Allosteric modulators of NR2B‐containing NMDA receptors: molecular mechanisms and therapeutic potential
Top Cited Papers
- 29 July 2009
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 157 (8) , 1301-1317
- https://doi.org/10.1111/j.1476-5381.2009.00304.x
Abstract
N‐methyl‐D‐aspartate receptors (NMDARs) are ion channels gated by glutamate, the major excitatory neurotransmitter in the mammalian central nervous system (CNS). They are widespread in the CNS and are involved in numerous physiological and pathological processes including synaptic plasticity, chronic pain and psychosis. Aberrant NMDAR activity also plays an important role in the neuronal loss associated with ischaemic insults and major degenerative disorders including Parkinson's and Alzheimer's disease. Agents that target and alter NMDAR function may, thus, have therapeutic benefit. Interestingly, NMDARs are endowed with multiple extracellular regulatory sites that recognize ions or small molecule ligands, some of which are likely to regulate receptor functionin vivo. These allosteric sites, which differ from agonist‐binding and channel‐permeation sites, provide means to modulate, either positively or negatively, NMDAR activity. The present review focuses on allosteric modulation of NMDARs containing the NR2B subunit. Indeed, the NR2B subunit confers a particularly rich pharmacology with distinct recognition sites for exogenous and endogenous allosteric ligands. Moreover, NR2B‐containing receptors, compared with other NMDAR subtypes, appear to contribute preferentially to pathological processes linked to overexcitation of glutamatergic pathways. The actions of extracellular H+, Mg2+, Zn2+, of polyamines and neurosteroids, and of the synthetic compounds ifenprodil and derivatives (‘prodils’) are presented. Particular emphasis is put upon the structural determinants and molecular mechanisms that underlie the effects exerted by these agents. A better understanding of how NR2B‐containing NMDARs (and NMDARs in general) operate and how they can be modulated should help define new strategies to counteract the deleterious effects of dysregulated NMDAR activity.Keywords
This publication has 169 references indexed in Scilit:
- In developing hippocampal neurons, NR2B-containing N-methyl-d-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal deathNeuroscience, 2009
- Binding of spermine and ifenprodil to a purified, soluble regulatory domain of theN‐methyl‐d‐aspartate receptorJournal of Neurochemistry, 2008
- Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonismMovement Disorders, 2008
- Enantiomeric Propanolamines as selectiveN-Methyl-d-aspartate 2B Receptor AntagonistsJournal of Medicinal Chemistry, 2008
- Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophreniaBrain Research, 2008
- Guide to Receptors and Channels (GRAC), 3rd editionBritish Journal of Pharmacology, 2008
- Structural Rearrangements of NR1/NR2A NMDA Receptors during Allosteric InhibitionNeuron, 2008
- Improving solubility of NR2B amino-terminal domain of N-methyl-d-aspartate receptor expressed in Escherichia coliBiochemical and Biophysical Research Communications, 2007
- A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1992
- Rapid-time-course miniature and evoked excitatory currents at cerebellar synapses in situNature, 1992